HealthQuill Drugs
The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults with early Alzheimer’s disease, including those with mild memory problems or mild dementia.
Drugs Health Pharma

FDA permits slow dosing of Eli Lilly’s Alzheimer’s drug Kisunla

HQ Team July 9, 2025: The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults.

Read More
Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion to gain access to a respiratory drug approved by the US regulator, according to a statement from Merck.
Drugs Health Pharma

Merck to acquire Verona Pharma for $10 billion to net respiratory drug 

HQ Team July 9, 2025: Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion and gain access to a.

Read More
Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss drug Wegovy, after trial data showed a third of participants losing 25% of their body weight.
Drugs Health Pharma

Novo Nordisk seeks EU nod for higher dose of its weight-loss drug Wegovy

HQ Team July 8, 2025: Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss.

Read More
Novartis AG’s treatment for malaria in infants and newborns weighing between two and five kilograms has been approved in Switzerland, and eight African nations are set to follow.
Drugs Health Pharma

Novartis malaria drug for infants gets Swiss nod, 8 African nations in line

HQ Team July 8, 2025: Novartis AG’s treatment for malaria in infants and newborns weighing between two and five kilograms has been approved.

Read More
Switzerland’s Basilea Pharmaceutica Ltd. has received an additional $39 million from the US-based Biomedical Advanced Research and Development Authority to continue to advance the end-stage trials of antifungals.
Drugs Medical Pharma

Basilea gets $39 million additional funds from US’s BARDA

HQ Team July 8, 2025: Switzerland’s Basilea Pharmaceutica Ltd. has received an additional $39 million from the US-based Biomedical Advanced Research and Development Authority to.

Read More
KalVista Pharmaceuticals Inc.'s medicine to treat hereditary angioedema, a rare disease that causes sudden and severe swelling attacks in the body, got approval from the US regulator. 
Drugs Health Pharma

KalVista’s oral pill for body swelling disorder gets US regulator’s nod 

HQ Team July 7, 2025: KalVista Pharmaceuticals Inc.’s medicine to treat hereditary angioedema, a rare disease that causes sudden and severe swelling attacks.

Read More
Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over 50 years, has failed to meet its primary goal of being symptom-free after a year of therapy.
Drugs Health Pharma

Novartis’ drug to treat inflammation of arteries fails in end-stage trials

HQ Team July 3, 2025: Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over.

Read More
The World Health Organization has unveiled a '3 by 35 initiative,’ urging governments to impose a health tax of about 50% on alcohol, sugary drinks and tobacco that are fuelling a noncommunicable disease (NCD) epidemic globally.
Drugs Health Pharma

Slap 50% tax on alcohol, sugary drinks, tobacco to curb NCDs: WHO

HQ Team July 3, 2025: The World Health Organization has unveiled a ‘3 by 35 initiative,’ urging governments to impose a health tax.

Read More
Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before, and the disease has recurred, has received the US regulator’s green light.
Drugs Health Pharma

Regenron’s drug to treat a type of blood cancer gets US regulator’s nod

HQ Team June 3, 2025: Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before,.

Read More
Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after it failed to meet its main efficacy goal.
Drugs Health Pharma

Organon halts endometriosis drug trial as it fails to meet efficacy goal

HQ Team July 2, 2025: Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after.

Read More